Objective To investigate the effect of recombinant human endostatin combined with chemotherapy on serum LMTK-3 and IGFBP-7 in patients with advanced non-small cell lung cancer. Methods Totally 86 cases of patients diagnosed with advanced non-small cell lung cancer in our hospital from January 2012 to January 2015 were involved in this study. Patients were randomly divided into observation group and control group (n = 43). Patients from control group received gemcitabine + cisplatin chemotherapy. Patients from observation group received endostar in addition to standard treatment. The therapeutic efficacy, side effects and concentration of VEGF, IGF-1, LMTK-3 and IGFBP were recorded. Results The therapeutic efficacy in observation group was significantly higher than that of the control group (χ2 = 5.403,7.493,P ＜ 0.05). No statistically significant difference in the incidence of adverse events between the two groups was observed. The levels of VEGF, IGF-1 and LMTK-3 in both groups were significantly increased while GFBP decreased post treatments when compared with that prior to treatments (P ＜ 0.05). Concentrations of VEGF, IGF-1 and LMTK-3 in observation group were downregulated while IGFBP-7 upregulated significantly when compared with control group (P ＜ 0.05). Conclusion Recombinant human endostatin combined with chemotherapy is a promising option for treatment of NSCLC patients with good efficacy and less adverse reactions.%目的 探讨重组人内皮抑素结合化疗对晚期非小细胞肺癌患者血清Lemur酪氨酸激酶3 (LMTK- 3)、胰岛素样生长因子结合蛋白7 (IGFBP-7)的影响.方法 选取2012年1月-2015年1月于该院收治的 NSCLC患者86例为研究对象,按随机数字表法分为观察组和对照组,每组43例.对照组患者采取吉西他滨+顺铂化疗.观察组在对照组基础上联合恩度治疗.对两组患者的临床疗效、不良反应、外周血血管内皮生长因子(VEGF)、胰岛素样生长因子1 (IGF-1)、LMTK-3、IGFBP表达水平进行评价.结果 观察组治疗客观有效率、总有效率高于对照组(P＜0.05),观察组的疗效优于对照组,差异有统计学意义(P＜0.05).两组患者的不良反应发生率并差异无统计学意义(P＞0.05).两组患者治疗后VEGF、IGF-1及LMTK-3水平较治疗前更低,GFBP水平较治疗后更高,差异有统计学意义(P＜0.05),且观察组治疗后VEGF、IGF-1及LMTK-3水平较对照组更低,IGFBP-7更高,差异有统计学意义(P＜0.05).结论 重组人内皮抑素联合化疗可有效降低 NSCLC患者的血清LMTK3水平,升高血清IGFBO-7水平,患者的疗效良好,不良反应较低.
展开▼
